Rituxan® and
MabThera® (generic name: Rituximab) are antibodies
used to treat rheumatoid arthritis, B cell non-Hodgkin's lymphoma, B cell leukemia, and some autoimmune
disorders. The widely-prescribed drug was developed by IDEC Pharmaceuticals and approved by the FDA in 1997.
In December of 2006,
the manufacturer of Rituxan issued an official warning
letter, advising healthcare professionals that Rituxan
has been linked to deaths of lupus
patients. These deaths occurred from the rare brain disease, Progressive
multifocal leukoencephalopathy (PML). This drastic
warning came barely a month after the manufacturer
had also issued an official warning, noting that Rituxan
can cause bowel obstruction and gastrointestinal perforation.
In some cases reported, Rituxan patients with bowel
obstruction and perforation have died from their injuries.
As of May, 2007, the official Rituxan website carries
the following warnings on the home page:
Fatal Infusion
Reactions: Deaths within 24 hours of RITUXAN infusion
have been reported. These fatal reactions followed
an infusion reaction complex, which included hypoxia,
pulmonary infiltrates, acute respiratory distress syndrome,
myocardial infarction, ventricular fibrillation, or
cardiogenic shock. Approximately 80% of fatal infusion
reactions occurred in association with the first infusion
Tumor Lysis Syndrome (TLS): Acute renal failure requiring
dialysis with instances of fatal outcome has been reported
in the setting of TLS following treatment of non-Hodgkin's
lymphoma (NHL) patients with RITUXAN.
Severe Mucocutaneous
Reactions: Severe mucocutaneous reactions, some with
fatal outcome, have been reported in association with
RITUXAN treatment.
Progressive Multifocal Leukoencephalopathy
(PML): JC virus infection resulting in PML and death
has been reported in patients treated with Rituxan.
The manufacturer of Rituxan warns patients to notify their
doctor prior to use if they have any of the following
conditions:
• Heart problems (angina, arrhythmias, etc.)
• Lung problems
• Hepatitis B virus
• High number of cancerous cells
• Kidney problems
Some of the most common side-effects noted with Rituxan
use are:
• Abnormal, black, bloody, tarry stools
• Bleeding gums
• Bloating/swelling of arms, hands, face, lower legs
• Blurred vision
• Persistent cough/hoarseness
• Increased thirst/hunger/urination
• Painful urination or difficulty urinating
• Stuffy/runny nose
• Nervousness
• Nausea, vomiting
• Unusual weight gain or loss
• Vomiting
For a full list, please see the manufacturer's
website at www.rituxan.com.
We have worked with many individuals and families who
have been injured by dangerous drugs. If you believe
Rituxan or MabThera use has put you or a loved
one in danger, please fill out our Case Review Contact
Form to the right on this page to find out what your
case is worth.
Dangerous Drugs
News Articles
Pfizer Starts Media Ad Blitz to Address Smoking Drug Concerns
May 28 (Bloomberg) – Pfizer Inc.
(read more..)
North Carolina Case Claims Financial Calamity From Bayer Drug
5/2/08 - Triangle Business Journal
(read more..)
Panel May Issue Subpoenas Related to FDA Approval
on Antibiotic Drug Ketek
1/28/08 - FDA
(read more..)
Second Safety Warning on Fentanyl Skin Patch
12/21/07 - FDA
(read more..)
F.D.A. Investigates Quit-Smoking Drug
11/20/07 - Associated Press
(read
more..)
Merck to Pay $4.85 Billion To Settle Most Vioxx Cases
11/09/07 - AngelReyesBlog.com
(read
more..)
Cephalon Drug Is Tied to Several Deaths
9/14/07 - The Wall Street Journal
(read
more..)
$5.5 Million Award in First Federal Fentanyl (Duragesic) Pain Patch Trial
6/19/07 - Press Release
(read
more...)